Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease

Gastroenterology

Volumn 139, Issue 2, 2010, Pages 456-463

  Dushay, Jody ^a   Chui, Patricia C ^a   Gopalakrishnan, Gosala S ^a   Varela Rey, Marta ^b   Crawley, Meghan ^a   Fisher, Folliott M ^a   Badman, Michael K ^a   Martinez Chantar, Maria L ^b   Maratos Flier, Eleftheria ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b CIC BIOGUNE   (Spain)

Author keywords

FGF21; NAFLD; NASH; Obesity

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; MESSENGER RNA; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; KETOGENIC DIET; LEAN BODY WEIGHT; NONALCOHOLIC FATTY LIVER; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; BLOOD; DIET RESTRICTION; FATTY LIVER; GENETICS; LIVER; MALE; METABOLISM; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TIME; UPREGULATION; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, WHITE; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; FASTING; FATTY LIVER; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KETOGENIC DIET; LIVER; MALE; NUTRITIONAL STATUS; OBESITY; PROSPECTIVE STUDIES; RNA, MESSENGER; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 77955474305     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.04.054     Document Type: Article

References (26)

1. T. Nishimura, Y. Nakatake, M. Konishi, and N. Itoh Identification of a novel FGF, FGF-21, preferentially expressed in the liver Biochem Biophys Acta 1492 2000 203 206
2. M. Badman, P. Pissios, A. Kennedy, et al. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states Cell Metab 5 2007 426 437
3. T. Inagaki, P. Dutchak, G. Zhao, et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21 Cell Metab 5 2007 415 425
4. A. Kharitonenkov, T. Shiyanova, A. Koester, et al. FGF-21 as a novel metabolic regulator J Clin Invest 115 2005 1627 1635
5. A. Kennedy, P. Pissios, H. Otu, et al. A high-fat, ketogenic diet induces a unique metabolic state in mice Am J Physiol Endocrinol Metab 292 2007 E1724 E1739
6. M. Badman, A. Koester, J. Flier, et al. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis Endocrinology 150 2009 1 10
7. T. Coskun, H. Bina, M. Schneider, et al. Fibroblast growth factor 21 corrects obesity in mice Endocrine 149 2008 6018 6027
8. E. Berglund, Y. Candice, H. Bina, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity Endocrinology 150 2009 4084 4093
9. W. Chen, L. Li, G. Yang, et al. Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus Exp Clin Endocrinol Diabetes 116 2008 65 68
10. X. Zhang, D. Yeung, M. Karpisek, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans Diabetes 57 2008 1246 1253
11. A. Chavez, M. Molina-Carrion, M. Abdul-Ghani, et al. Circulating fibroblast growth factor 21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance Diabetes Care 32 2009 1542 1546
12. H. Li, Y. Bao, A. Xu, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects J Clin Endocrin Metab 94 2009 2151 2156
13. I. Dostalova, P. Kavalkova, D. Haluzikova, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa J Clin Endocrinol Metab 93 2008 3627 3632
14. C. Galman, T. Lundasen, A. Kharitonenkov, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man Cell Metab 8 2009 169 174
15. C. Christodoulides, P. Dyson, D. Sprecher, et al. Circulating FGF21 is induced by PPAR agonists but not ketosis in man J Clin Endocrin Metab 94 2009 3594 3601
16. M. Mraz, M. Bartlova, Z. Lacinova, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity Clin Endocrinol 71 2009 369 375
17. J. Sanchez, A. Palou, and C. Pico Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction Endocrinology 150 2009 1 10
18. J. Xu, S. Stanislaus, and N. Chinookoswong Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin resistant mouse models - association with liver and adipose tissue effects Am J Physiol Endocrinol Metab 2009 Aug 25 [Epub ahead of print]
19. A. Kharitonenkov, V.J. Wroblewski, A. Koester, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21 Endocrinology 148 2007 774 781
20. L. Li, G. Yang, H. Ning, et al. Plasma FGF-21 levels in type 2 diabetic patients with ketosis Diabetes Res Clin Pract 82 2008 209 213
21. M. Badman, A. Kennedy, A. Adams, et al. A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independent of weight loss Am J Physiol Endocrinol Metab 297 2009 E1197 E1204
22. T. Lundasen, M.C. Hunt, L.M. Nilsson, et al. PPARalpha is a key regulator of hepatic FGF21 Biochem Biophys Res Commun 360 2007 437 440
23. J.D. Browning, L.S. Szczepaniak, R. Dobbins, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395
24. T.T. Tran, C. Changsri, C.R. Shackelton, et al. Living donor liver transplantation: histologic abnormalities found on liver biopsies of apparently healthy potential donors J Gastroenterol Hepatol 21 2006 381 383
25. M. Lazo, and J. Clark The epidemiology of nonalcoholic fatty liver disease: a global perspective Semin Liv Dis 28 2008 339 350
26. B. Neuschwander-Teri, and S. Caldwell Nonalcoholic steatohepatitis: summary of AASLD single topic conference Hepatology 37 2003 1202 1219